Here are the 10-Q quarterly reports from Revelation Biosciences, Inc. Warrant (REVBW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow REVBW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full REVBW filings page.
Revelation Biosciences, Inc. (REVB), a clinical-stage developer of GEM-AKI and GEM-CKD, reported a nine-month net loss of $9,647,948, versus $6,402,643 for the nine months ended September 30, 2025. Operating expenses were $10,138,317, including $4,808,183 in research and development; $2,247,519 was for GEM-AKI.
Cash and cash equivalents were $9,121,630 as of September 30, 2026. Operating activities used $8,133,206 during the nine months; financing activities provided $6,666,012, primarily from the January Class I warrant inducement. The company has never generated revenue and says its cash is not expected to sustain operations within one year after the September 30, 2026 statements were issued, which raises substantial doubt about its ability to continue as a going concern. It plans to seek additional equity or debt financing.
Revelation says its current listed-securities market value is below $5 million. Nasdaq's rule requires automatic delisting if it remains below that threshold for 30 consecutive business days, and becomes operative upon termination of the SEC stay. On October 20, 2026, the company effected a 1-for-7 reverse split, adjusting specified warrant exercise prices from $12.46 to $3.29 and Class G underlying shares from 489,250 to 1,852,908.
Revelation Biosciences, a clinical-stage biotech developing Gemini-based kidney therapies GEM-AKI and GEM-CKD, reported a Q2 2026 net loss of $3.3 million and a six-month net loss of $6.3 million. Operating expenses increased as GEM-AKI clinical and manufacturing spend, new facility costs, and stock-based compensation rose.
Cash and cash equivalents were $11.5 million and total assets $12.5 million as of June 30, 2026, with stockholders’ equity of $10.1 million and an accumulated deficit of $55.8 million. Since inception, the company has raised $75.9 million, including $6.7 million in January 2026 from a Class I warrant inducement, and had 3.9 million common shares outstanding plus 8.9 million shares underlying warrants.
Management states that existing cash will not sustain operations for 12 months after issuance of these financial statements, creating substantial doubt about continuing as a going concern. After quarter-end, Revelation adopted a stockholder rights plan and described potential Nasdaq delisting risk under a proposed $5 million market-value continued listing rule.
Revelation Biosciences (REVB) reported another loss-making quarter as it advances kidney disease programs GEM‑AKI and GEM‑CKD. For the three months ended March 31, 2026, the company posted a net loss of $3.0 million, wider than $2.1 million a year earlier.
Operating expenses rose to $3.1 million, driven by higher GEM‑AKI development and manufacturing costs, stock-based compensation, and new facility expenses. Cash and cash equivalents increased to $14.1 million, helped by $6.7 million of net proceeds from a Class I warrant inducement, while shares outstanding more than doubled to 3,908,420.
Management states current cash will not sustain operations for 12 months after the financial statements were issued, raising substantial doubt about the company’s ability to continue as a going concern. Revelation expects to seek additional equity or debt financing, and holds significant outstanding warrants that could further affect existing shareholders.